{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T06:58:17Z","timestamp":1761893897858,"version":"3.33.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2004,2,1]],"date-time":"2004-02-01T00:00:00Z","timestamp":1075593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,2,1]],"date-time":"2004-02-01T00:00:00Z","timestamp":1075593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2004,2]]},"DOI":"10.1136\/ard.2003.006775","type":"journal-article","created":{"date-parts":[[2004,1,13]],"date-time":"2004-01-13T20:08:12Z","timestamp":1074024492000},"page":"156-161","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"title":["Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patients"],"prefix":"10.1016","volume":"63","author":[{"given":"M","family":"Feletar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J E","family":"Brockbank","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C T","family":"Schentag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V","family":"Lapp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D D","family":"Gladman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/ard.2003.006775_bib1","series-title":"Kelly\u2019s textbook of rheumatology","first-page":"1071","article-title":"Psoriatic arthritis","author":"Gladman","year":"2001"},{"key":"10.1136\/ard.2003.006775_bib2","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0950-3579(94)80017-0","article-title":"Psoriatic arthritis: historical background and epidemiology","volume":"8","author":"O\u2019Neill","year":"1994","journal-title":"Baillieres Clin Rheumatol"},{"key":"10.1136\/ard.2003.006775_bib3","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0889-857X(05)70044-2","article-title":"Psoriatic arthritis [review]","volume":"24","author":"Gladman","year":"1998","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1136\/ard.2003.006775_bib4","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.2165\/00003495-200262170-00004","article-title":"Diagnosis and management of psoriatic arthritis","volume":"62","author":"Brockbank","year":"2002","journal-title":"Drugs"},{"key":"10.1136\/ard.2003.006775_bib5","first-page":"518","article-title":"Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid","volume":"24","author":"Partsch","year":"1997","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2003.006775_bib6","first-page":"1544","article-title":"Patterns of cytokine production in psoriatic synovium","volume":"25","author":"Ritchlin","year":"1998","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2003.006775_bib7","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/1529-0131(200101)44:1<186::AID-ANR25>3.0.CO;2-B","article-title":"Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondyloarthropathy. Histologic findings in eight patients from an open\u2013label pilot study","volume":"44","author":"Baeten","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2003.006775_bib8","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1136\/ard.61.3.213","article-title":"Differential association of polymorphisms in the TNFalpha region with psoriatic arthritis but not psoriasis","volume":"61","author":"Hohler","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2003.006775_bib9","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/rheumatology\/41.5.525","article-title":"Tumour necrosis factor-alpha polymorphism and the HLA-Cw*0602 allele in psoriatic arthritis","volume":"41","author":"Al\u2013Heresh","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard.2003.006775_bib10","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","article-title":"Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial","volume":"356","author":"Mease","year":"2000","journal-title":"Lancet"},{"issue":"suppl 9","key":"10.1136\/ard.2003.006775_bib11","first-page":"S90","article-title":"Improvement in disease activity in patients with psoriatic arthritis receiving etanercept (Enbrel\u00ae): results of a phase 3 multicenter clinical trial [abstract]","volume":"44","author":"Mease","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"suppl 9","key":"10.1136\/ard.2003.006775_bib12","first-page":"S985","article-title":"The infliximab multinational psoriatic arthritis controlled trial (IMPACT) [abstract]","volume":"46","author":"Antoni","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2003.006775_bib13","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1002\/1529-0131(199911)42:11<2325::AID-ANR10>3.0.CO;2-C","article-title":"Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondyloarthropathies. A Department of Veterans Affairs cooperative study","volume":"42","author":"Clegg","year":"1999","journal-title":"Arthritis Rheum"},{"issue":"suppl 9","key":"10.1136\/ard.2003.006775_bib14","first-page":"S442","article-title":"Etanercept (Enbrel\u00ae) inhibits radiographic progression in patients with psoriatic arthritis [abstract]","volume":"46","author":"Ory","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2003.006775_bib15","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0140-6736(94)90628-9","article-title":"Randomised double\u2013blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis","volume":"344","author":"Elliott","year":"1994","journal-title":"Lancet"},{"key":"10.1136\/ard.2003.006775_bib16","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","article-title":"Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti\u2013Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group","volume":"343","author":"Lipsky","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2003.006775_bib17","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","article-title":"Therapeutic efficacy of multiple intravenous infusions of anti\u2013tumour necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis","volume":"41","author":"Maini","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2003.006775_bib18","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/art.10671","article-title":"Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation","volume":"47","author":"Antoni","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2003.006775_bib19","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/S0140-6736(00)04954-0","article-title":"Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial","volume":"357","author":"Chaudhari","year":"2001","journal-title":"Lancet"},{"key":"10.1136\/ard.2003.006775_bib20","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/00002281-199002040-00004","article-title":"Psoriatic arthritis [review]","volume":"2","author":"Gladman","year":"1990","journal-title":"Curr Opin Rheumatol"},{"key":"10.1136\/ard.2003.006775_bib21","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000250839","article-title":"Severe psoriasis\u2014oral therapy with a new retinoid","volume":"157","author":"Fredriksson","year":"1978","journal-title":"Dermatologica"},{"key":"10.1136\/ard.2003.006775_bib22","first-page":"511","article-title":"Validating the SF\u201336 health questionnaire in patients with Psoriatic Arthritis","volume":"24","author":"Husted","year":"1997","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2003.006775_bib23","first-page":"439","article-title":"Modified HAQ in psoriatic arthritis","volume":"13","author":"Husted","year":"1995","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard.2003.006775_bib24","first-page":"886","article-title":"Measuring health status in psoriatic arthritis: the Health Assessment Questionnaire and its modification","volume":"22","author":"Blackmore","year":"1995","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2003.006775_bib25","first-page":"1627","article-title":"Fatigue in psoriatic arthritis (PsA)","volume":"26","author":"Schentag","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2003.006775_bib26","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1093\/rheumatology\/37.7.760","article-title":"Radiological assessment in psoriatic arthritis","volume":"37","author":"Rahman","year":"1998","journal-title":"Br J Rheumatol"},{"key":"10.1136\/ard.2003.006775_bib27","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00296-002-0246-3","article-title":"Treatment of psoriatic arthritis and psoriasis vulgaris with the tumor necrosis factor inhibitor infliximab","volume":"22","author":"Cauza","year":"2002","journal-title":"Rheumatol Int"},{"key":"10.1136\/ard.2003.006775_bib28","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1046\/j.1468-3083.2002.00391.x","article-title":"Treatment of recalcitrant psoriatic arthritis with anti-tumor necrosis factor-alpha antibody","volume":"16","author":"Wollina","year":"2002","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1136\/ard.2003.006775_bib29","first-page":"644","article-title":"The effectiveness of tumor necrosis factor alpha antibody (infliximab) in treating recalcitrant psoriasis: a report of 2 cases","volume":"138","author":"O\u2019Quinn","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1136\/ard.2003.006775_bib30","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1067\/mjd.2002.120472","article-title":"Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab","volume":"46","author":"Schopf","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1136\/ard.2003.006775_bib31","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/art.511","article-title":"Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor \u03b1 (infliximab) versus placebo in active spondyloarthropathy","volume":"46","author":"Van den Bosch","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2003.006775_bib32","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1136\/ard.61.3.207","article-title":"Repeated infusions of infliximab, a chimeric anti-TNF alpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up","volume":"61","author":"Kruithof","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2003.006775_bib33","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","article-title":"Treatment of active AS with infliximab: a randomized controlled multicentre trial","volume":"359","author":"Braun","year":"2002","journal-title":"Lancet"},{"key":"10.1136\/ard.2003.006775_bib34","first-page":"959","article-title":"Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety","volume":"29","author":"Maksymowych","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2003.006775_bib35","first-page":"1605","article-title":"Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis","volume":"28","author":"Stone","year":"2001","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2003.006775_bib36","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/0002-9343(91)90667-M","article-title":"Methotrexate and histologic hepatic abnormalities: a meta-analysis","volume":"90","author":"Whiting\u2013O\u2019Keefe","year":"1991","journal-title":"Am J Med"},{"key":"10.1136\/ard.2003.006775_bib37","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0140-6736(02)07714-0","article-title":"Drug-induced systemic lupus erythematosus associated with etanercept therapy","volume":"359","author":"Shakoor","year":"2002","journal-title":"Lancet"},{"key":"10.1136\/ard.2003.006775_bib38","doi-asserted-by":"crossref","first-page":"625","DOI":"10.7326\/0003-4819-137-7-200210010-00030","article-title":"Infliximab-induced systemic lupus erythematosus","volume":"137","author":"Ali","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard.2003.006775_bib39","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1191\/0961203302lu236cr","article-title":"Drug-induced lupus following treatment with infliximab in rheumatoid arthritis","volume":"11","author":"Favalli","year":"2002","journal-title":"Lupus"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724085522?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724085522?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.2003.006775","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T04:55:15Z","timestamp":1737348915000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724085522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,2]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,2]]}},"alternative-id":["S0003496724085522"],"URL":"https:\/\/doi.org\/10.1136\/ard.2003.006775","relation":{},"ISSN":["0003-4967"],"issn-type":[{"type":"print","value":"0003-4967"}],"subject":[],"published":{"date-parts":[[2004,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patients","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.2003.006775","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 Copyright 2004 by Annals of the Rheumatic Diseases, Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}